戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 HOXA9 in glioblastoma (GBM), the most common malignant brain tumor.
2 n medulloblastoma, the most common childhood malignant brain tumor.
3        Glioblastoma (GBM) is the most common malignant brain tumor.
4 lioblastoma (GBM) is the most common primary malignant brain tumor.
5 the hypoxic region of glioblastoma, the most malignant brain tumor.
6 anner in glioblastoma (GBM), the most common malignant brain tumor.
7 Medulloblastoma is the most common pediatric malignant brain tumor.
8      Glioblastoma is the most common primary malignant brain tumor.
9 a is both the most common and lethal primary malignant brain tumor.
10 ations in the normal brain, and is common in malignant brain tumors.
11 ctive against a variety of tumors, including malignant brain tumors.
12  brain and that this pathway is subverted in malignant brain tumors.
13 get for new anti-invasive therapies to treat malignant brain tumors.
14  cells remaining after surgical debulking of malignant brain tumors.
15  of this approach in patients with recurrent malignant brain tumors.
16  option for patients with certain benign and malignant brain tumors.
17 ance in improving survival for patients with malignant brain tumors.
18 00 in treating both adults and children with malignant brain tumors.
19 m the suggested benefit from temozolomide in malignant brain tumors.
20 en infused intratumorally into patients with malignant brain tumors.
21  of IL-13R complex in 25 primary explants of malignant brain tumors.
22 in cellular immunotherapy trials for primary malignant brain tumors.
23 llular immunotherapy trials in human primary malignant brain tumors.
24   High-grade gliomas are the most aggressive malignant brain tumors.
25 erapy for some young children with recurrent malignant brain tumors.
26 atients with progressive growth of recurrent malignant brain tumors.
27 or experimental treatment of uniformly fatal malignant brain tumors.
28 cue (ABMR) for young patients with recurrent malignant brain tumors.
29 ft models, to determine its activity against malignant brain tumors.
30 ent antiproliferative activity against human malignant brain tumors.
31 tment-related changes (TRC) in patients with malignant brain tumors.
32 tem, accounting for approximately 80% of all malignant brain tumors.
33 e TBI was associated with risk of developing malignant brain tumors.
34 n extracellular matrix (ECM) are involved in malignant brain tumors.
35 ty in recurrent GBM, with potential in other malignant brain tumors.
36 f implementation in personalized medicine of malignant brain tumors.
37 enefit after standard of care has failed for malignant brain tumors.
38 e of high-grade glioma and other progressive malignant brain tumors.
39 or heterogeneity and geographic evolution of malignant brain tumors.
40                     Glioblastomas are highly malignant brain tumors.
41 ne therapy approaches to treat patients with malignant brain tumors.
42 appaB signaling in combination therapies for malignant brain tumors.
43 all central nervous system tumors and 80% of malignant brain tumors.
44 ative thrombosis in patients with benign and malignant brain tumors.
45 rove the treatment outcomes of patients with malignant brain tumors.
46 lymerases, resulting in 'ultra-hypermutated' malignant brain tumors.
47  as well as diseases, including most notably malignant brain tumors.
48  receiving radiotherapy for the treatment of malignant brain tumors.
49 y contribute to the etiology of these highly malignant brain tumors.
50 that can improve management of patients with malignant brain tumors.
51 ession of the anti-bacterial gene deleted in malignant brain tumor 1 (DMBT1) is mediated by p38 and S
52                                     Lethal 3 malignant brain tumor 1 (L3MBTL1), a homolog of the Dros
53               Further, we find that lethal 3 malignant brain tumor 1 (L3MBTL1), a reader protein with
54 like, Ap15a-like, and ApNp35) and Deleted in Malignant Brain Tumor 1-like proteins.
55 ation and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the alia
56                               The deleted in malignant brain tumors 1 (DMBT1) gene on 10q25-26 is a c
57 ernatively spliced product of the deleted in malignant brain tumors 1 (DMBT1) gene.
58 y agglutinin [SAG, encoded by the deleted in malignant brain tumors 1 (DMBT1) gene] is an innate immu
59 sephosphate isomerase (TPI1), and deleted in malignant brain tumors 1 protein (DMBT1).
60                            Dmbt1 (deleted in malignant brain tumors 1) was identified as a candidate
61 e further show that expression of Deleted in Malignant Brain Tumors 1, the human homologue of the col
62                  Glioblastoma is a prevalent malignant brain tumor and despite clinical intervention,
63 astoma multiforme is the most common primary malignant brain tumor and despite treatment with surgery
64               Glioblastoma (GBM) is the most malignant brain tumor and is highly resistant to intensi
65 ultiforme is the most common type of primary malignant brain tumor and may arise from a cell with neu
66 GB is the most common and aggressive primary malignant brain tumor and the current standard-of-care t
67 de gliomas (LGG) are the most common primary malignant brain tumors and are resistant to current ther
68 el therapeutic strategy for the treatment of malignant brain tumors and confirm the antitumor activit
69 B opening for drug delivery in patients with malignant brain tumors and effectively facilitate BBB cl
70  treatment related morbidity in infants with malignant brain tumors and in older children with standa
71 a multiforme (GBM) is one of the most common malignant brain tumors and its average survival time is
72  cell surface receptors are overexpressed in malignant brain tumors and reportedly involved in tumor
73  the rationale for targeting angiogenesis in malignant brain tumors and summarizes the results of rec
74      Glioblastoma is the most common primary malignant brain tumor, and is refractory to surgical res
75 deadly cancer, is the most lethal and common malignant brain tumor, and the leading cause of death in
76           Gliomas account for 77% of primary malignant brain tumors, and the prognosis has hardly cha
77             From a structural point of view, malignant brain tumors are classically characterized by
78                         Approximately 49% of malignant brain tumors are glioblastomas, and 30% are di
79 ndividuals, and approximately 49% of primary malignant brain tumors are glioblastomas.
80                                              Malignant brain tumors are highly lethal and aggressive.
81 s of glioma, the most common type of primary malignant brain tumor, are poorly understood.
82    Glioblastomas (GBMs), the most common and malignant brain tumors, are highly resistant to current
83 or in 20 patients with pathologically proven malignant brain tumors (astrocytoma, n = 17; oligodendro
84       The primary outcome was development of malignant brain tumor based on International Classificat
85 iving acute lymphoblastic leukemia (ALL) and malignant brain tumors (BTs) have a higher incidence of
86      Glioblastoma is the most common primary malignant brain tumor, but despite multimodal treatment
87 stoma (GBM) is the most common type of adult malignant brain tumor, but its molecular mechanisms are
88 ma multiforme, the most common adult primary malignant brain tumor, but not in grade II to III glioma
89 ese studies offer a new concept for treating malignant brain tumors by improving the accumulation of
90    A significant proportion of children with malignant brain tumors can avoid radiotherapy and prolon
91              Potent immune responses against malignant brain tumors can be elicited by paracrine intr
92 ted the routine clinical care of challenging malignant brain tumor cases at a U.S. institution.
93 el in which the spatio-temporal expansion of malignant brain tumor cells is guided by environmental h
94                              TM-601 binds to malignant brain tumor cells with high affinity and does
95               Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous p
96                    Glioblastoma is a primary malignant brain tumor characterized by highly infiltrati
97               Glioblastoma (GBM) is the most malignant brain tumor characterized by intrinsic or acqu
98          Medulloblastoma (MB) is a pediatric malignant brain tumor composed of four different subgrou
99                                              Malignant brain tumors consist of a number of distinct s
100                                              Malignant brain tumors consist of malignancies originate
101                    Traditional therapies for malignant brain tumors consist of surgical resection and
102  (GBM) is the most common and lethal primary malignant brain tumor, containing GBM stem cells (GSCs)
103  Nervous System Lymphomas (PCNSLs) are rare, malignant brain tumors derived from lymphocytes B.
104                                      Diffuse malignant brain tumors develop during early embryogenesi
105                         Medulloblastoma is a malignant brain tumor diagnosed in children.
106                       The protein deleted in malignant brain tumors (DMBT1) and the trefoil factor (T
107 ike family of proteins, often accompanied by malignant brain tumor domain (MBT) and sterile alpha mot
108                        SFMBT1 belongs to the malignant brain tumor domain-containing chromatin reader
109 ide screen, we identified Scm-like with four malignant brain tumor domains 1 (SFMBT1) as a candidate
110   We present a protocol for using the triple malignant brain tumor domains of L3MBTL1 (3xMBT), which
111 BT1 (Scm [Sex comb on midleg] with four MBT [malignant brain tumor] domains 1) is a poorly characteri
112                      The dismal prognosis of malignant brain tumors drives the development of new tre
113 resected tumors of 26 patients with advanced malignant brain tumors enrolled during December 2020 to
114                                  In archival malignant brain tumors expression levels of ALK and PTN
115 omplexes, polycomb repressive complexes, and malignant brain tumor family proteins, that collectively
116 pressor protein, the product of the lethal(3)malignant brain tumor gene.
117 endent intercellular signaling of the highly malignant brain tumor glioblastoma multiforme (GBM).
118 bitors for many tumors, including the highly malignant brain tumor glioblastoma.
119 ealed a number of miRNAs dysregulated in the malignant brain tumor glioblastoma.
120 romising therapeutic strategy for the highly malignant brain tumor, glioblastoma (GBM).
121 reat cancer, however, its efficacy in highly malignant brain-tumors, glioblastomas (GBM), is limited.
122 CL12 and its cognate receptor CXCR4 regulate malignant brain tumor growth and are potential chemother
123  lymphoblastic leukemia, hepatoblastoma, and malignant brain tumors had the highest risk of early dea
124 stoma (GBM), the most common type of primary malignant brain tumors harboring a subpopulation of stem
125        Glioblastoma, the most common primary malignant brain tumor, harbors a small population of tum
126  the activation of developmental programs in malignant brain tumors has emerged as a driver for growt
127          Glioblastoma, the predominant adult malignant brain tumor, has been computationally classifi
128  glioblastoma (GBM), the most common primary malignant brain tumor, have been defined, the intricate
129 re TBI group had a higher risk of developing malignant brain tumors (hazard ratio [HR], 1.67 [95% CI,
130 f medulloblastoma, the most common childhood malignant brain tumor: However, many long-term survivors
131 lioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a dismal pro
132              Glioblastoma is the most common malignant brain tumor in adults and carries a particular
133 ligodendrogliomas are the second most common malignant brain tumor in adults and exhibit characterist
134      Glioblastoma is the most common primary malignant brain tumor in adults and is associated with p
135   Glioblastoma is the most prevalent primary malignant brain tumor in adults and is characterized by
136 lioblastoma (GBM) is the most common primary malignant brain tumor in adults with a poor prognosis de
137  glioblastoma (GBM), the most common primary malignant brain tumor in adults, remains a significant u
138 own in glioblastoma, the most common primary malignant brain tumor in adults.
139  (GBM) is the most common and lethal primary malignant brain tumor in adults.
140 ioblastoma multiforme (GBM), the most common malignant brain tumor in adults.
141 lioblastoma (GBM) is the most common primary malignant brain tumor in adults.
142      Glioblastoma is the most lethal primary malignant brain tumor in adults.
143 astoma is the most common and lethal primary malignant brain tumor in adults.
144 o medulloblastoma formation, the most common malignant brain tumor in childhood.
145 igh-grade glioma (pHGG) is the most frequent malignant brain tumor in children and can be subclassifi
146           Medulloblastoma is the most common malignant brain tumor in children, and despite improveme
147   Medulloblastoma (MB) is the most prevalent malignant brain tumor in children, exhibiting clinical a
148             Medulloblastoma, the most common malignant brain tumor in children, is a biologically het
149     Medulloblastoma, the most common primary malignant brain tumor in children, is a radiosensitive a
150 eatment for medulloblastoma, the most common malignant brain tumor in children, remains limited to su
151 a subset of medulloblastoma, the most common malignant brain tumor in children, was found to contain
152      Medulloblastoma (MB) is the most common malignant brain tumor in children, where one-third of pa
153           Medulloblastoma is the most common malignant brain tumor in children.
154 tly linked to medulloblastoma (MB), a common malignant brain tumor in children.
155  that collectively represent the most common malignant brain tumor in children.
156 ve rise to medulloblastomas, the most common malignant brain tumor in children.
157  leading to medulloblastoma, the most common malignant brain tumor in children.
158 ormation in medulloblastoma, the most common malignant brain tumor in children.
159 l models of medulloblastoma, the most common malignant brain tumor in children.
160 combination therapy to treat the most common malignant brain tumor in children.
161 lts in medulloblastoma (MB), the most common malignant brain tumor in children.
162  origin for medulloblastoma, the most common malignant brain tumor in children.
163 on promotes medulloblastoma, the most common malignant brain tumor in children.
164 nating in the cerebellum, is the most common malignant brain tumor in children.
165 ciated with medulloblastoma, the most common malignant brain tumor in children.
166      Medulloblastoma (MB) is the most common malignant brain tumor in children.
167           Medulloblastoma is the most common malignant brain tumor in children.Chromosome arm 17p13.3
168                     Glioblastoma is the most malignant brain tumor in humans and an average survival
169               Astrocytoma is the most common malignant brain tumor in humans.
170              Glioblastoma is the most common malignant brain tumor in humans.
171  poor prognosis, are the most common primary malignant brain tumors in adults.
172 e the most prevalent and devastating primary malignant brain tumors in adults.
173             Medulloblastoma, one of the most malignant brain tumors in children, is thought to arise
174     Medulloblastoma is among the most common malignant brain tumors in children.
175 omprise medulloblastoma, are the most common malignant brain tumors in children.
176 ma-derived myc (N-myc) is a leading cause of malignant brain tumors in children.
177 otherapy resulted in a high response rate of malignant brain tumors in infants.
178                                  Symptoms of malignant brain tumors include headache (50%), seizures
179                                        Other malignant brain tumors include primary central nervous s
180  system and the efficacy of gene therapy for malignant brain tumors include: 1) the design of more ef
181 dality of therapy for all commonly occurring malignant brain tumors, including medulloblastoma and gl
182              The annual incidence of primary malignant brain tumors is approximately 7 per 100 000 in
183                     The incidence of primary malignant brain tumors is approximately 7 per 100 000 in
184           Evaluation of treatment effects in malignant brain tumors is challenging because of the lac
185   Medulloblastoma, the most common pediatric malignant brain tumor, is an example of a disease that h
186 Glioblastoma, the most common and aggressive malignant brain tumor, is propagated by stem-like cancer
187                MB, the most common pediatric malignant brain tumor, is treated with surgical resectio
188 blastoma multiforme, the most common form of malignant brain tumor,is resistant to all forms of thera
189 gene delivery in gene therapy strategies for malignant brain tumors, it is important to determine the
190 ogue of Drosophila tumor suppressor lethal(3)malignant brain tumor (l(3)mbt), binds histones in a met
191                 Here, we identified Lethal(3)malignant brain tumor-like protein 1 (L3MBTL1) as a key
192                                       Lethal malignant brain tumors (lmbt) result from the loss of th
193 his mechanism persists in medulloblastoma, a malignant brain tumor markedly sensitive to radiation an
194                                              Malignant brain tumor (MBT) domain of PHF20L1 binds to m
195 ded abrogating binding of the Polycomb group malignant brain tumor (MBT) protein L3MBTL1 to lysine me
196 tial recognition of p53K382me1 by the triple malignant brain tumor (MBT) repeats of the chromatin com
197          Human L3MBTL1, which contains three malignant brain tumor (MBT) repeats, binds monomethylate
198 61, which encodes a protein composed of four malignant brain tumor (MBT) repeats.
199                      We demonstrate that the malignant-brain-tumor (MBT) protein L3MBTL1 is in a comp
200      Glioblastoma is the most common primary malignant brain tumor of adults and one of the most leth
201              Glioblastoma is the most common malignant brain tumor of adults and one of the most leth
202             Medulloblastoma, the most common malignant brain tumor of childhood, is believed to deriv
203 uggest that medulloblastoma, the most common malignant brain tumor of childhood, is comprised of four
204      Medulloblastoma (MB) is the most common malignant brain tumor of childhood.
205                  Medulloblastoma is a common malignant brain tumor of childhood.
206           Medulloblastoma is the most common malignant brain tumor of childhood.
207 ulloblastomas (PNET/MB), are the most common malignant brain tumor of childhood.
208      Medulloblastoma (MB) is the most common malignant brain tumor of children.
209         Medulloblastomas are the most common malignant brain tumors of childhood, and despite recent
210    Medulloblastoma is one of the most common malignant brain tumors of children, and 30% of medullobl
211 e blood-brain barrier (BBB) in patients with malignant brain tumors or metastases.
212 roliferation of abnormal microvasculature in malignant brain tumor patients, we have undertaken a cel
213          Caregivers of patients with primary malignant brain tumors (PMBT) experience significant psy
214                                              Malignant brain tumors pose diagnostic and therapeutic p
215                                              Malignant brain tumor prevalence was 0.6% in the moderat
216 the human homolog of the Drosophila lethal(3)malignant brain tumor protein, is a member of the polyco
217 ranscriptional repressor protein, lethal (3) malignant brain tumor protein, L(3)MBT, and the histone
218                                              Malignant brain tumors rank among the most challenging t
219 s without systemic toxicity in patients with malignant brain tumors refractory to conventional therap
220               In spite of intensive studies, malignant brain tumors remain to be a medical challenge.
221 apies, the clinical outcome of patients with malignant brain tumors remains extremely poor.
222  with Glioblastoma Multiforme (GM), a highly malignant brain tumor, remains poor despite concerted ef
223                         It contains two MBT (malignant brain tumor) repeats; the MBT is a protein mod
224                     Gliomas, the most common malignant brain tumors, represent the main focus of the
225  AAV-miRzip-21 and AAV-miR-7 in mice bearing malignant brain tumors resulted in significantly decreas
226         Mutations in any of three genes [l(3)malignant brain tumor, shackleton, and out of sync] affe
227 TB) is a major obstacle for drug delivery to malignant brain tumors such as glioblastoma (GBM).
228 egion, and rearrangements or inactivation in malignant brain tumors, suggest that LGI1 is a candidate
229                         Medulloblastoma is a malignant brain tumor that arises in the cerebellum in c
230                    Medulloblastoma (MB) is a malignant brain tumor that arises in the cerebellum of c
231             Medulloblastoma (MB) is a highly malignant brain tumor that occurs primarily in children.
232                    Medulloblastoma (MB) is a malignant brain tumor that often arises in the cerebellu
233                           Gliomas are highly malignant brain tumors that are highly invasive and resi
234                            Glioblastomas are malignant brain tumors that are very difficult to cure,
235                         Medulloblastomas are malignant brain tumors that arise by transformation of n
236                         Medulloblastomas are malignant brain tumors that arise in the cerebellum in c
237                         Medulloblastomas are malignant brain tumors that arise in the cerebellum in c
238                          Diffuse gliomas are malignant brain tumors that include lower-grade gliomas
239 ermal tumors (PNETs) are a family of primary malignant brain tumors that include medulloblastomas.
240 A relatively novel combination treatment for malignant brain tumors that includes focused ultrasound
241            Glioblastomas are highly vascular malignant brain tumors that often overexpress vascular e
242 ight of clinical trials of oncolytic HSV for malignant brain tumors, these findings suggest that anti
243                     Given the propensity for malignant brain tumors to infiltrate the surrounding nor
244 owever, the immune escape mechanisms used by malignant brain tumors to subvert this innate type of im
245 microenvironment might affect the ability of malignant brain tumors to traverse between brain and vas
246 lationships in newly diagnosed patients with malignant brain tumors treated with direct injections of
247 al antibody (MAb) in patients with recurrent malignant brain tumors, treated by direct injections of
248     New approaches to treating patients with malignant brain tumors use advanced magnetic resonance a
249  an effective agent used in the treatment of malignant brain tumors, was examined in an animal tumor
250 CXCL12 is a stroma-derived growth factor for malignant brain tumors, we tested the hypothesis that CX
251 (median age, 30 months) with newly diagnosed malignant brain tumors were enrolled onto this trial.
252 98 children younger than 3 years of age with malignant brain tumors were treated with prolonged posto
253 lastoma, one of the most prevalent childhood malignant brain tumors, were investigated to identify pr
254 cer drug discovery projects, but not yet for malignant brain tumors where type-II inhibition of cycli
255 erential regulation of cell proliferation in malignant brain tumors, which will have a broader impact
256 n younger than 6 years of age with recurrent malignant brain tumors who had not previously been expos
257           Glioblastoma multiforme (GBM) is a malignant brain tumor with a poor prognosis resulting fr
258 lioblastomas (GBMs), the most common primary malignant brain tumor with an unfavorable prognosis.
259                      Glioblastoma (GBM) is a malignant brain tumor with diffuse infiltration.
260 toma multiforme (GBM) is a highly aggressive malignant brain tumor with fatal outcome.
261              Glioblastoma is the most common malignant brain tumor with less than 15 months median su
262 lioblastoma (GBM) is a highly aggressive and malignant brain tumor with limited therapeutic options a
263        Glioblastoma (GBM) is the most common malignant brain tumor with poor prognosis under the curr
264     Glioblastoma (GBM) is the most prevalent malignant brain tumor with poor prognosis.
265 ma is the most common and aggressive primary malignant brain tumor with poor prognosis.
266 glioma/GBM) is the most common primary adult malignant brain tumor with poor prognosis.
267                     Glioblastomas (GBMs) are malignant brain tumors with a median survival of less th
268 s intracranial growth in xenograft models of malignant brain tumors with comparable efficacy to AMD 3
269                                 Treatment of malignant brain tumors with conventional approaches is l
270 igh-grade glioma (HGG) is a group of primary malignant brain tumors with dismal prognosis.
271 e investigated regional therapy of recurrent malignant brain tumors with transferrin-CRM107, a conjug
272 lastoma (GBM) is the most aggressive primary malignant brain tumor, with a median survival of approxi
273 ain tumor, accounting for nearly half of all malignant brain tumors, with a median survival rate of o
274 alignant gliomas are the most common primary malignant brain tumors, with an annual incidence of 5.26

 
Page Top